

Ida Martinelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2020960/publications.pdf>

Version: 2024-02-01

202
papers

17,936
citations

20817

60
h-index

13379

130
g-index

205
all docs

205
docs citations

205
times ranked

12626
citing authors

#	ARTICLE	IF	CITATIONS
1	Oral Rivaroxaban for Symptomatic Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2010, 363, 2499-2510.	27.0	2,807
2	Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. <i>New England Journal of Medicine</i> , 2012, 366, 1287-1297.	27.0	2,080
3	High Risk of Cerebral-Vein Thrombosis in Carriers of a Prothrombin-Gene Mutation and in Users of Oral Contraceptives. <i>New England Journal of Medicine</i> , 1998, 338, 1793-1797.	27.0	647
4	Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. <i>Blood</i> , 2018, 132, 1365-1371.	1.4	573
5	The Risk of Recurrent Deep Venous Thrombosis among Heterozygous Carriers of Both Factor V Leiden and the G20210A Prothrombin Mutation. <i>New England Journal of Medicine</i> , 1999, 341, 801-806.	27.0	467
6	European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis – endorsed by the European Academy of Neurology. <i>European Journal of Neurology</i> , 2017, 24, 1203-1213.	3.3	434
7	EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients. <i>European Journal of Neurology</i> , 2010, 17, 1229-1235.	3.3	420
8	Different Risks of Thrombosis in Four Coagulation Defects Associated With Inherited Thrombophilia: A Study of 150 Families. <i>Blood</i> , 1998, 92, 2353-2358.	1.4	378
9	Mutations in Coagulation Factors in Women with Unexplained Late Fetal Loss. <i>New England Journal of Medicine</i> , 2000, 343, 1015-1018.	27.0	296
10	Risk factors for venous and arterial thrombosis. <i>Blood Transfusion</i> , 2011, 9, 120-38.	0.4	294
11	High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis.. <i>Arteriosclerosis and Thrombosis: A Journal of Vascular Biology</i> , 1994, 14, 1080-1083.	3.9	243
12	EFNS guideline on the treatment of cerebral venous and sinus thrombosis. <i>European Journal of Neurology</i> , 2006, 13, 553-559.	3.3	241
13	Effects on health of air pollution: a narrative review. <i>Internal and Emergency Medicine</i> , 2015, 10, 657-662.	2.0	200
14	Hyperhomocysteinemia in cerebral vein thrombosis. <i>Blood</i> , 2003, 102, 1363-1366.	1.4	197
15	Effects of exposure to air pollution on blood coagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 252-260.	3.8	191
16	Risk factors for thrombophilia in extrahepatic portal vein obstruction. <i>Hepatology</i> , 2005, 41, 603-608.	7.3	190
17	The risk of recurrent venous thromboembolism in pregnancy and puerperium without antithrombotic prophylaxis. <i>British Journal of Haematology</i> , 2006, 135, 386-391.	2.5	185
18	Exposure to Particulate Air Pollution and Risk of Deep Vein Thrombosis. <i>Archives of Internal Medicine</i> , 2008, 168, 920.	3.8	184

#	ARTICLE	IF	CITATIONS
19	Long-term Clinical Outcomes of Splanchnic Vein Thrombosis. <i>JAMA Internal Medicine</i> , 2015, 175, 1474.	5.1	180
20	A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism. <i>Blood</i> , 2004, 104, 3631-3634.	1.4	179
21	Risk Factors in Venous Thromboembolism. <i>Thrombosis and Haemostasis</i> , 2001, 86, 395-403.	3.4	176
22	Inherited Thrombophilia and First Venous Thromboembolism during Pregnancy and Puerperium. <i>Thrombosis and Haemostasis</i> , 2002, 87, 791-795.	3.4	173
23	Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. <i>Lancet Haematology</i> , 2020, 7, e18-e27.	4.6	173
24	Risk Factors and Recurrence Rate of Primary Deep Vein Thrombosis of the Upper Extremities. <i>Circulation</i> , 2004, 110, 566-570.	1.6	172
25	Interaction Between the G20210A Mutation of the Prothrombin Gene and Oral Contraceptive Use in Deep Vein Thrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 700-703.	2.4	170
26	Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials. <i>Lancet</i> , 2016, 388, 2629-2641.	13.7	167
27	Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. <i>Blood</i> , 2016, 127, 1417-1425.	1.4	156
28	European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis – Endorsed by the European Academy of Neurology. <i>European Stroke Journal</i> , 2017, 2, 195-221.	5.5	144
29	Risk of Venous Thromboembolism After Air Travel. <i>Archives of Internal Medicine</i> , 2003, 163, 2771.	3.8	141
30	Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetetrahydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls. <i>European Journal of Epidemiology</i> , 2013, 28, 621-647.	5.7	141
31	Cerebral venous sinus thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1918-1931.	3.8	137
32	Factor V Gene Mutation Is a Risk Factor for Cerebral Venous Thrombosis. <i>Thrombosis and Haemostasis</i> , 1996, 75, 393-394.	3.4	136
33	Meta-analysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications. <i>Blood</i> , 2014, 123, 822-828.	1.4	130
34	Inherited Thrombophilia and Pregnancy Complications Revisited. <i>Obstetrics and Gynecology</i> , 2008, 112, 320-324.	2.4	127
35	Thrombotic risk factors: Basic pathophysiology. <i>Critical Care Medicine</i> , 2010, 38, S3-S9.	0.9	126
36	Living Near Major Traffic Roads and Risk of Deep Vein Thrombosis. <i>Circulation</i> , 2009, 119, 3118-3124.	1.6	122

#	ARTICLE	IF	CITATIONS
37	Genetic Risk Factors for Superficial Vein Thrombosis. <i>Thrombosis and Haemostasis</i> , 1999, 82, 1215-1217.	3.4	121
38	Long-Term Evaluation of the Risk of Recurrence After Cerebral Sinus-Venous Thrombosis. <i>Circulation</i> , 2010, 121, 2740-2746.	1.6	120
39	Risk of Pregnancy-related Venous Thrombosis in Carriers of Severe Inherited Thrombophilia. <i>Thrombosis and Haemostasis</i> , 2001, 86, 800-803.	3.4	119
40	Splanchnic vein thrombosis: clinical presentation, risk factors and treatment. <i>Internal and Emergency Medicine</i> , 2010, 5, 487-494.	2.0	118
41	Inherited risk factors for venous thromboembolism. <i>Nature Reviews Cardiology</i> , 2014, 11, 140-156.	13.7	118
42	von Willebrand factor and factor VIII as risk factors for arterial and venous thrombosis. <i>Seminars in Hematology</i> , 2005, 42, 49-55.	3.4	116
43	Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. <i>Blood</i> , 2012, 119, 3269-3275.	1.4	106
44	Risk Factors for Deep Venous Thrombosis of the Upper Extremities. <i>Annals of Internal Medicine</i> , 1997, 126, 707.	3.9	100
45	Circulating microparticles and risk of venous thromboembolism. <i>Thrombosis Research</i> , 2012, 129, 591-597.	1.7	92
46	The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. <i>British Journal of Haematology</i> , 2000, 111, 1223-1229.	2.5	89
47	The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation. <i>British Journal of Haematology</i> , 2001, 113, 630-635.	2.5	80
48	Inherited Thrombophilic Risk Factors and Venous Thromboembolism. <i>Chest</i> , 2000, 118, 1405-1411.	0.8	79
49	Marburg I polymorphism of factor VII-activating protease and risk of venous thromboembolism. <i>Blood</i> , 2006, 107, 1731-1731.	1.4	73
50	The endogenous thrombin potential and the risk of venous thromboembolism. <i>Thrombosis Research</i> , 2007, 121, 353-359.	1.7	73
51	Venous thromboembolism in women: a specific reproductive health risk. <i>Human Reproduction Update</i> , 2013, 19, 471-482.	10.8	73
52	Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant. <i>Thrombosis Research</i> , 2015, 135, 46-49.	1.7	70
53	High levels of factor VIII and risk of extra-hepatic portal vein obstruction. <i>Journal of Hepatology</i> , 2009, 50, 916-922.	3.7	69
54	Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. <i>Blood</i> , 1998, 92, 2353-8.	1.4	69

#	ARTICLE	IF	CITATIONS
55	A meta-analysis of low-molecular-weight heparin to prevent pregnancy loss in women with inherited thrombophilia. <i>Blood</i> , 2016, 127, 1650-1655.	1.4	67
56	Air Pollution, Smoking, and Plasma Homocysteine. <i>Environmental Health Perspectives</i> , 2007, 115, 176-181.	6.0	64
57	Low borderline plasma levels of antithrombin, protein C and protein S are risk factors for venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1783-1791.	3.8	63
58	The JAK2 V617F mutation in patients with cerebral venous thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 998-1003.	3.8	61
59	Risk factors in venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2001, 86, 395-403.	3.4	61
60	Embryo implantation after assisted reproductive procedures and maternal thrombophilia. <i>Haematologica</i> , 2003, 88, 789-93.	3.5	61
61	Additional genetic risk factors for venous thromboembolism in carriers of the factor V Leiden mutation. <i>British Journal of Haematology</i> , 1998, 103, 871-876.	2.5	60
62	Pros and cons of thrombophilia testing: pros. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 410-411.	3.8	60
63	Low Prevalence of Factor V:Q506 in 41 Patients with Isolated Pulmonary Embolism. <i>Thrombosis and Haemostasis</i> , 1997, 77, 440-443.	3.4	60
64	Vascular disorders of the liver: Recommendations from the Italian Association for the Study of the Liver (AISF) ad hoc committee. <i>Digestive and Liver Disease</i> , 2011, 43, 503-514.	0.9	59
65	Hyperhomocysteinemia as a Risk Factor for Deep-Vein Thrombosis. <i>New England Journal of Medicine</i> , 1996, 335, 974-976.	27.0	58
66	Long-Term Outcome of Splanchnic Vein Thrombosis in Cirrhosis. <i>Clinical and Translational Gastroenterology</i> , 2018, 9, e176.	2.5	57
67	Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry. <i>Lancet Haematology</i> , 2016, 3, e267-e275.	4.6	55
68	Risk factors for idiopathic sudden sensorineural hearing loss and their association with clinical outcome. <i>Thrombosis Research</i> , 2015, 135, 508-512.	1.7	54
69	How I treat rare venous thromboses. <i>Blood</i> , 2008, 112, 4818-4823.	1.4	53
70	Next-generation sequencing study finds an excess of rare, coding single-nucleotide variants of ADAMTS13 in patients with deep vein thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1228-1239.	3.8	52
71	Pulmonary embolism in a young pregnant woman with COVID-19. <i>Thrombosis Research</i> , 2020, 191, 36-37.	1.7	52
72	Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein Jr phase 3 dose-exposure-response evaluation. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1672-1685.	3.8	52

#	ARTICLE	IF	CITATIONS
73	Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies. <i>Lancet Haematology</i> , 2019, 6, e500-e509.	4.6	51
74	Hemostatic Abnormalities in Noonan Syndrome. <i>Pediatrics</i> , 2014, 133, e1299-e1304.	2.1	49
75	Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT). <i>Blood Advances</i> , 2020, 4, 6250-6258.	5.2	49
76	Screening for thrombophilia and antithrombotic prophylaxis in pregnancy: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). <i>Thrombosis Research</i> , 2009, 124, e19-e25.	1.7	48
77	Rare thromboses of cerebral, splanchnic and upper-extremity veins. <i>Thrombosis and Haemostasis</i> , 2010, 103, 1136-1144.	3.4	48
78	Type and location of venous thromboembolism in patients with factor V Leiden or prothrombin G20210A and in those with no thrombophilia. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 98-101.	3.8	43
79	Platelet to Lymphocyte Ratio and Neutrophil to Lymphocyte Ratio as Risk Factors for Venous Thrombosis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 808-814.	1.7	43
80	The relationship between plasma homocysteine levels and bone mineral density in post-menopausal women. <i>European Journal of Internal Medicine</i> , 2010, 21, 301-305.	2.2	42
81	Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms: An European LeukemiaNet study. <i>American Journal of Hematology</i> , 2014, 89, E200-5.	4.1	42
82	Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 531-535.	3.8	40
83	The value of 18F-FDG PET/CT in the assessment of active idiopathic retroperitoneal fibrosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1635-1642.	6.4	39
84	Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia. <i>Thrombosis and Haemostasis</i> , 2001, 86, 800-3.	3.4	39
85	The risk of first venous thromboembolism during pregnancy and puerperium in double heterozygotes for factor V Leiden and prothrombin G20210A. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 494-498.	3.8	38
86	Heightened Thrombin Generation in Individuals with Resistance to Activated Protein C. <i>Thrombosis and Haemostasis</i> , 1996, 75, 703-705.	3.4	38
87	Safety of Pregnancy After Cerebral Venous Thrombosis. <i>Stroke</i> , 2017, 48, 3130-3133.	2.0	37
88	Comparison of adverse drug reactions among four COVID-19 vaccines in Europe using the EudraVigilance database: Thrombosis at unusual sites. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2554-2558.	3.8	37
89	Early-onset ischaemic stroke: Analysis of 58 polymorphisms in 17 genes involved in methionine metabolism. <i>Thrombosis and Haemostasis</i> , 2010, 104, 231-242.	3.4	35
90	Venous Thrombosis Risk after Cast Immobilization of the Lower Extremity: Derivation and Validation of a Clinical Prediction Score, L-TRiP(cast), in Three Population-Based Case-Control Studies. <i>PLoS Medicine</i> , 2015, 12, e1001899.	8.4	35

#	ARTICLE	IF	CITATIONS
91	Association between red cell distribution width and risk of venous thromboembolism. <i>Thrombosis Research</i> , 2015, 136, 590-594.	1.7	34
92	Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban. <i>Haematologica</i> , 2018, 103, e315-e317.	3.5	34
93	Hemostatic alterations in COVID-19. <i>Haematologica</i> , 2021, 106, 1472-1475.	3.5	34
94	Oral contraceptive use, thrombophilia and their interaction in young women with ischemic stroke. <i>Haematologica</i> , 2006, 91, 844-7.	3.5	34
95	Plasma Levels of Activated Protein C in Healthy Subjects and Patients With Previous Venous Thromboembolism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1998, 18, 1371-1375.	2.4	33
96	Anticoagulant Treatment With Rivaroxaban in Severe Protein S Deficiency. <i>Pediatrics</i> , 2013, 132, e1435-e1439.	2.1	33
97	Low levels of protein Z and the risk of venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 2817-2819.	3.8	32
98	Thromboembolism in Women. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 709-715.	2.7	32
99	Identification of genetic risk variants for deep vein thrombosis by multiplexed next-generation sequencing of 186 hemostatic/pro-inflammatory genes. <i>BMC Medical Genomics</i> , 2012, 5, 7.	1.5	32
100	Cerebral Thrombosis and Myeloproliferative Neoplasms. <i>Current Neurology and Neuroscience Reports</i> , 2014, 14, 496.	4.2	32
101	Uncertain thrombophilia markers. <i>Thrombosis and Haemostasis</i> , 2016, 115, 25-30.	3.4	32
102	PDMS content affects in vitro hemocompatibility of synthetic vascular grafts. <i>Journal of Materials Science: Materials in Medicine</i> , 2007, 18, 1097-1104.	3.6	31
103	Pregnancy loss and risk of ischaemic stroke and myocardial infarction. <i>British Journal of Haematology</i> , 2016, 174, 302-309.	2.5	31
104	Increasing dosages of low-molecular-weight heparin in hospitalized patients with Covid-19. <i>Internal and Emergency Medicine</i> , 2021, 16, 1223-1229.	2.0	31
105	Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. <i>Thrombosis and Haemostasis</i> , 2002, 87, 791-5.	3.4	31
106	Levothyroxine suppressive therapy for solitary thyroid nodule. <i>Journal of Endocrinological Investigation</i> , 1995, 18, 796-799.	3.3	30
107	Unusual forms of venous thrombosis and thrombophilia. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2002, 32, 343-345.	0.3	30
108	Prothrombin A19911G polymorphism and the risk of venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 2582-2586.	3.8	30

#	ARTICLE	IF	CITATIONS
109	Cerebral sinus-venous thrombosis. <i>Internal and Emergency Medicine</i> , 2012, 7, 221-225.	2.0	29
110	Normal reference ranges of antithrombin, protein C and protein S: Effect of sex, age and hormonal status. <i>Thrombosis Research</i> , 2013, 132, e152-e157.	1.7	29
111	Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study. <i>Thrombosis Journal</i> , 2018, 16, 31.	2.1	29
112	Risk of post-operative venous thromboembolism in patients with meningioma. <i>Journal of Neuro-Oncology</i> , 2018, 138, 401-406.	2.9	28
113	Abdominal thromboses of splanchnic, renal and ovarian veins. <i>Best Practice and Research in Clinical Haematology</i> , 2012, 25, 253-264.	1.7	27
114	Thrombophilic and cardiovascular risk factors for retinal vein occlusion. <i>European Journal of Internal Medicine</i> , 2017, 44, 44-48.	2.2	27
115	Hemostatic abnormalities in patients with Ehlers-Danlos syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 2425-2431.	3.8	27
116	Risk of cerebral vein thrombosis and oral contraceptives. <i>Lancet</i> , The, 1998, 352, 326.	13.7	25
117	Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper. <i>Blood Cancer Journal</i> , 2019, 9, 61.	6.2	25
118	Mild hyperhomocysteinemia is associated with increased TAFI levels and reduced plasma fibrinolytic potential. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1571-7.	3.8	24
119	Low-molecular-weight heparin for prevention of placenta-mediated pregnancy complications: protocol for a systematic review and individual patient data meta-analysis (AFFIRM). <i>Systematic Reviews</i> , 2014, 3, 69.	5.3	24
120	Apolipoprotein(a) Kringle-IV Type 2 Copy Number Variation Is Associated with Venous Thromboembolism. <i>PLoS ONE</i> , 2016, 11, e0149427.	2.5	24
121	The use of LMWH in pregnancies at risk: new evidence or perception?. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 778-779.	3.8	23
122	Towards the genetic basis of cerebral venous thrombosis—the BEAST Consortium: a study protocol: Table A1. <i>BMJ Open</i> , 2016, 6, e012351.	1.9	23
123	Polymorphisms of the protein Z-dependent protease inhibitor (ZPI) gene and the risk of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2006, 95, 909-910.	3.4	21
124	Risk of thrombosis in women with malignancies undergoing ovarian stimulation for fertility preservation. <i>Human Reproduction Update</i> , 2014, 20, 944-951.	10.8	21
125	The “Pregnancy Health-care Program” for the prevention of venous thromboembolism in pregnancy. <i>Internal and Emergency Medicine</i> , 2015, 10, 129-134.	2.0	20
126	Treatment of unusual thrombotic manifestations. <i>Blood</i> , 2020, 135, 326-334.	1.4	20

#	ARTICLE	IF	CITATIONS
127	Oral Contraceptives Are a Risk Factor for Cerebral Vein Thrombosis. <i>Thrombosis and Haemostasis</i> , 1996, 76, 477-478.	3.4	20
128	Resistance to activated protein C in unselected patients with arterial and venous thrombosis. <i>American Journal of Hematology</i> , 1997, 55, 59-64.	4.1	19
129	Thrombophilic states. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 120, 1061-1071.	1.8	19
130	Comparative analysis of full-time, half-time, and quarter-time myocardial ECG-gated SPECT quantification in normal-weight and overweight patients. <i>Journal of Nuclear Cardiology</i> , 2017, 24, 876-887.	2.1	19
131	The effect of recanalization on long-term neurological outcome after cerebral venous thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 718-724.	3.8	19
132	Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study. <i>Blood Advances</i> , 2022, 6, 3569-3578.	5.2	19
133	Seasonal variation of venous thrombosis: a consecutive case series within studies from Leiden, Milan and TromsÅ, <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1704-1707.	3.8	18
134	Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria phenotype in patients with splanchnic vein thrombosis. <i>Thrombosis Research</i> , 2014, 133, 1052-1055.	1.7	17
135	Fibrin clot structure is affected by levels of particulate air pollution exposure in patients with venous thrombosis. <i>Environment International</i> , 2016, 92-93, 70-76.	10.0	17
136	Targeted sequencing to identify novel genetic risk factors for deep vein thrombosis: a study of 734 genes. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 2432-2441.	3.8	17
137	Findings from a multicentre, observational study on reproductive outcomes in women with unexplained recurrent pregnancy loss: the OTTILIA registry. <i>Human Reproduction</i> , 2021, 36, 2083-2090.	0.9	17
138	Prognostic value of hemostatic parameters after liver transplantation. <i>Journal of Hepatology</i> , 1992, 15, 125-128.	3.7	16
139	Genetic risk factors for superficial vein thrombosis. <i>Thrombosis and Haemostasis</i> , 1999, 82, 1215-7.	3.4	16
140	Cerebral vein thrombosis. <i>Thrombosis Research</i> , 2013, 131, S51-S54.	1.7	15
141	Pregnancy outcome after a first episode of cerebral vein thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 2386-2393.	3.8	15
142	Red cell distribution width and the risk of cerebral vein thrombosis: A case-control study. <i>European Journal of Internal Medicine</i> , 2017, 38, 46-51.	2.2	15
143	Risk of pregnancy-related venous thromboembolism and obstetrical complications in women with inherited type I antithrombin deficiency: a retrospective, single-centre, cohort study. <i>Lancet Haematology</i> , 2020, 7, e320-e328.	4.6	15
144	Recurrent Late Fetal Death in Women with and without Thrombophilia. <i>Thrombosis and Haemostasis</i> , 2002, 87, 358-359.	3.4	14

#	ARTICLE	IF	CITATIONS
145	Pharmacogenetic aspects of the use of oral contraceptives and the risk of thrombosis. <i>Pharmacogenetics and Genomics</i> , 2003, 13, 589-594.	5.7	14
146	Hormone therapy and thromboembolic disease. <i>Current Opinion in Internal Medicine</i> , 2007, 6, 607-612.	1.5	14
147	Where do we stand with antithrombotic prophylaxis in patients with COVID-19?. <i>Thrombosis Research</i> , 2020, 191, 29.	1.7	14
148	Thrombin generation and other coagulation parameters in a patient with homozygous congenital protein S deficiency on treatment with rivaroxaban. <i>International Journal of Hematology</i> , 2016, 103, 165-172.	1.6	13
149	ADAMTS13 activity, high VWF and FVIII levels in the pathogenesis of deep vein thrombosis. <i>Thrombosis Research</i> , 2021, 197, 132-137.	1.7	13
150	Molecular characterization of an Italian patient with plasminogen deficiency and ligneous conjunctivitis. <i>Blood Coagulation and Fibrinolysis</i> , 2007, 18, 81-84.	1.0	12
151	Influence of anticoagulant therapy with vitamin K antagonists on plasma levels of coagulation factor VIII. <i>Thrombosis Research</i> , 2010, 126, 243-245.	1.7	12
152	Duration of oral contraceptive use and the risk of venous thromboembolism. A case-control study. <i>Thrombosis Research</i> , 2016, 141, 153-157.	1.7	11
153	Thrombotic Storm in a Teenager With Previously Undiagnosed Ulcerative Colitis. <i>Pediatrics</i> , 2013, 131, e1288-e1291.	2.1	10
154	Genome-Wide Association Study Identifies First Locus Associated with Susceptibility to Cerebral Venous Thrombosis. <i>Annals of Neurology</i> , 2021, 90, 777-788.	5.3	10
155	Cerebral Vein Thrombosis In Patients With Myeloproliferative Neoplasms. <i>Blood</i> , 2013, 122, 4068-4068.	1.4	10
156	Polymorphisms of the protein Z-dependent protease inhibitor (ZPI) gene and the risk of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2006, 95, 909-10.	3.4	10
157	RE: "VALIDATED QUESTIONNAIRE FOR THE IDENTIFICATION OF PREVIOUS PERSONAL OR FAMILIAL VENOUS THROMBOEMBOLISM". <i>American Journal of Epidemiology</i> , 1998, 147, 605-606.	3.4	9
158	Extra-abdominal venous thromboses at unusual sites. <i>Best Practice and Research in Clinical Haematology</i> , 2012, 25, 265-274.	1.7	9
159	Influence of proband's characteristics on the risk for venous thromboembolism in relatives with factor V Leiden or prothrombin G20210A polymorphisms. <i>Blood</i> , 2013, 122, 2555-2561.	1.4	9
160	Single Nucleotide Variant rs2232710 in the Protein Z-Dependent Protease Inhibitor (ZPI, SERPINA10) Gene Is Not Associated with Deep Vein Thrombosis. <i>PLoS ONE</i> , 2016, 11, e0151347.	2.5	9
161	Recommendations for prophylaxis of pregnancy-related venous thromboembolism in carriers of inherited thrombophilia. Comment on the 2012 ACCP guidelines. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1779-1781.	3.8	8
162	Plasma levels of extracellular vesicles and the risk of post-operative pulmonary embolism in patients with primary brain tumors: a prospective study. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 224-231.	2.1	8

#	ARTICLE	IF	CITATIONS
163	Thrombosis after liver transplantation for hepatocellular carcinoma. PLoS ONE, 2017, 12, e0186699.	2.5	8
164	Interrelation of Hyperhomocyst(e)inemia, Factor V Leiden, and Risk of Future Venous Thromboembolism. Circulation, 1998, 97, 295-296.	1.6	7
165	CD18 promoter methylation is associated with a higher risk of thrombotic complications in primary myelofibrosis. Annals of Hematology, 2016, 95, 1965-1969.	1.8	7
166	Next-Generation Sequencing and In Vitro Expression Study of ADAMTS13 Single Nucleotide Variants in Deep Vein Thrombosis. PLoS ONE, 2016, 11, e0165665.	2.5	7
167	The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. British Journal of Haematology, 2000, 111, 1223-1229.	2.5	6
168	Low risk of thrombosis in family members of patients with hyperhomocysteinaemia. British Journal of Haematology, 2002, 117, 709-711.	2.5	6
169	Thrombophilia testing. Journal of Thrombosis and Haemostasis, 2003, 1, 1311-1312.	3.8	6
170	Prothrombin Mutation Conveying Antithrombin Resistance. New England Journal of Medicine, 2012, 367, 1069-1070.	27.0	6
171	Antithrombotic prophylaxis in a patient with nephrotic syndrome and congenital protein S deficiency. Italian Journal of Pediatrics, 2016, 42, 22.	2.6	6
172	Hemostasis in pregnant women with COVID-19. International Journal of Gynecology and Obstetrics, 2021, 152, 268-269.	2.3	6
173	Risk factors for mortality in hospitalized patients with COVID-19: a study in Milan, Italy. Infectious Diseases, 2021, 53, 226-229.	2.8	6
174	Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high- and low-dose rivaroxaban with aspirin. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 308-313.	2.3	6
175	Role of ADAMTS13, VWF and F8 genes in deep vein thrombosis. PLoS ONE, 2021, 16, e0258675.	2.5	6
176	Vitamin K antagonists in children with central venous catheter on chronic haemodialysis: a pilot study. Pediatric Nephrology, 2016, 31, 827-832.	1.7	5
177	Pregnancy after cerebral venous thrombosis. Thrombosis Research, 2019, 181, S15-S18.	1.7	5
178	Embryo implantation after assisted reproductive procedures and maternal thrombophilia. Journal of Thrombosis and Haemostasis, 2003, 1, P0344-P0344.	3.8	5
179	Pregnancy-associated deep vein thrombosis in a double homozygous carrier of factor V Leiden and prothrombin G20210A. Thrombosis and Haemostasis, 2005, 94, 1329-1330.	3.4	4
180	Effect of prothrombin 19911 A>G polymorphism on the risk of cerebral sinus venous thrombosis. European Journal of Neurology, 2010, 17, 1482-1485.	3.3	4

#	ARTICLE	IF	CITATIONS
181	Next-generation DNA sequencing to identify novel genetic risk factors for cerebral vein thrombosis. <i>Thrombosis Research</i> , 2018, 169, 76-81.	1.7	4
182	Frequency of Factor V Arg506 Gin in Italians. <i>Thrombosis and Haemostasis</i> , 1996, 75, 694-694.	3.4	4
183	Ischemic stroke in congenital (type II C) defective antithrombin III. <i>International Journal of Clinical and Laboratory Research</i> , 1993, 23, 212-214.	1.0	3
184	Laboratory Measures of Hemostasis for Monitoring Liver Graft Function. <i>Seminars in Thrombosis and Hemostasis</i> , 1993, 19, 238-242.	2.7	3
185	Activated partial thromboplastin time: results of a case-control study evaluating six commercial reagents in assessing the risk of venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 1407-1409.	3.8	3
186	Platelet activation in subjects carrying factor V Leiden or factor II A20210 mutations. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 2496-2498.	3.8	3
187	Haemostatic Activation in HIV Infected Patients Treated with Different Antiretroviral Regimens. <i>Current HIV Research</i> , 2008, 6, 70-76.	0.5	3
188	Recurrent late fetal death in women with and without thrombophilia. <i>Thrombosis and Haemostasis</i> , 2002, 87, 358-9.	3.4	3
189	Prognostic value of the activated partial thromboplastin time after orthotopic liver transplantation. <i>International Journal of Clinical and Laboratory Research</i> , 1994, 24, 220-222.	1.0	2
190	Absence of antibodies to tissue-type plasminogen activator in patients with previous deep vein thrombosis. <i>International Journal of Clinical and Laboratory Research</i> , 1998, 28, 72-73.	1.0	2
191	Counselling women about hormonal therapy. <i>Thrombosis Research</i> , 2009, 123, S74-S78.	1.7	2
192	Safety of anticoagulant treatment in patients with non-malignant non-cirrhotic extrahepatic portal vein obstruction. <i>Internal and Emergency Medicine</i> , 2011, 6, 95-96.	2.0	2
193	Pregnancy outcome after a first episode of cerebral vein thrombosis: reply. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1526-1526.	3.8	2
194	Prognostic value of the activated partial thromboplastin time after orthotopic liver transplantation: a prospective study. <i>Journal of Hepatology</i> , 1994, 21, 917.	3.7	1
195	Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 1184-1185.	3.8	1
196	The use of LMWH in pregnancies at risk: new evidence or perception?. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 789-790.	3.8	1
197	Response: Anticoagulation in splanchnic vein thrombosis. <i>Blood</i> , 2009, 113, 5032-5032.	1.4	1
198	Low-Molecular-Weight Heparin and Recurrent Placenta-Mediated Pregnancy Complications: A Meta-analysis of Individual Patient Data From Randomised Controlled Trials. <i>Obstetrical and Gynecological Survey</i> , 2017, 72, 153-155.	0.4	1

#	ARTICLE	IF	CITATIONS
199	The risk of cesarean delivery after labor induction among women with prior pregnancy complications: a subgroup analysis of the AFFIRM study. <i>BMC Pregnancy and Childbirth</i> , 2019, 19, 455.	2.4	1
200	Reply: Risk Factors for Deep Venous Thrombosis of the Upper Extremities. <i>Annals of Internal Medicine</i> , 1997, 127, 1129.	3.9	0
201	Reply to a Rebuttal: Counseling Pregnant Women Homozygous for Factor V Leiden. <i>Thrombosis and Haemostasis</i> , 2002, 87, 361-361.	3.4	0
202	Interaction between inherited thrombophilia and HIV infection: fact or fancy?. <i>Nature Reviews Cardiology</i> , 2014, 11, 321-321.	13.7	0